RxDoctor Payments DataLook up a doctor →

Mohannad Bisharat, MD

Interventional Cardiology · Pampa, TXNPI 1134459472

Payments from drug & device makers

$870,113in general payments, 2019–2025

Across 1,514 payments — averaging $574.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$191K
  • Inari Medical, Inc.$189K
  • Janssen Research & Development, LLC$166K
  • Amgen$146K
  • Abbott$48K
  • AstraZeneca$23K
  • plus $106K from 54 others
$300in research payments, 2019–2025

Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$300

What the payments were for

  • Consulting fees$99,40049%
  • Speaking & faculty fees$62,73031%
  • Travel & lodging$6,5043%
  • Food & beverage$32,23216%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alnylam Pharmaceuticals Inc.231$190,918
Inari Medical, Inc.156$189,114
Janssen Research & Development, LLC35$166,089
Amgen128$145,669
Abbott66$48,384
AstraZeneca10$23,415
Stryker136$18,101
Bard Peripheral Vascular, Inc.44$17,426
Endovascular Engineering Inc.6$15,827
Angiodynamics, Inc.20$13,293
Medtronic(2 entities)154$9,645
Cardiovascular Systems Inc.70$7,356
Wilson Cook Medical Incorporated1$4,635
Abiomed44$3,847
Penumbra, Inc.43$2,920
Philips North America LLC36$2,623
Argon Medical Devices, Inc.5$1,735
Boston Scientific48$1,328
Novo Nordisk AS48$1,167
Cook Medical LLC21$754
Cvrx, Inc.11$456
Impulse Dynamics (USA) Inc.12$374
Novartis8$321
Pfizer18$321
Shockwave Medical, Inc8$301
Venclose Inc.3$299
Johnson & Johnson25$295
Contego Medical, Inc2$269
Amarin Pharma, Inc.16$254
Reflow Medical Inc9$236
Boehringer Ingelheim4$208
Terumo Medical Corporation2$201
E.r. Squibb & Sons, L.L.C.6$195
Baxter Healthcare9$177
Imperative Care, Inc4$168
Merck9$141
Bardy Diagnostics, Inc.13$128
Actelion Pharmaceuticals US, Inc.5$126
Heartflow, Inc.1$124
Surmodics, Inc.1$116
Avinger Inc.7$116
Sanofi-aventis U.S. LLC5$112
Edwards Lifesciences1$105
Endologix LLC1$102
Asahi Intecc USA, Inc.1$100
Teleflex LLC2$94
Scpharmaceuticals Inc.4$75
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$61
W. L. Gore & Associates, Inc.3$56
Cardinal Health 200 LLC2$46
Kiniksa Pharmaceuticals International, PLC2$44
Bridgebio Pharma, Inc.1$30
Siemens Medical Solutions USA, Inc.1$27
Novo Nordisk1$26
Astellas Pharma US Inc1$22
Esperion Therapeutics, Inc.1$21
Kiniksa Pharmaceuticals, Ltd.1$21
Coloplast1$21
Cardio Flow, Inc.1$19
Ionis Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870,113 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$1,547,772
Medicare patients
516
Services billed
3,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$91,902
EntrestoSacubitril/Valsartan60$60,470
Repatha SureclickEvolocumab64$47,297
XareltoRivaroxaban35$26,860
FarxigaDapagliflozin Propanediol15$14,700
ClopidogrelClopidogrel Bisulfate164$1,873
Prasugrel Hcl11$927
Losartan Potassium61$512
Atorvastatin Calcium63$510
Metoprolol Succinate42$481
Nifedipine ErNifedipine18$295
Amlodipine Besylate27$282
Rosuvastatin Calcium25$282
Cilostazol16$248
Carvedilol36$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$321$91,902108 claims
NovartisEntresto$321$60,47060 claims
Johnson & JohnsonXarelto$295$26,86035 claims
AstraZenecaFarxiga$23,415$14,70015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Pampa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →